Tesamorelin + Ipamorelin common uses, half-life, side effects and more

Tesamorelin + Ipamorelin pairs a prescription growth hormone releasing hormone analog with an unapproved ghrelin receptor agonist. People use the pair to raise their own growth hormone and IGF-1 without injecting growth hormone itself. The usual goals are body composition, visceral fat, sleep, and recovery. Tesamorelin on its own is an approved prescription drug in the United States for one narrow use. That use is excess belly fat in adults with HIV who have lipodystrophy. Ipamorelin and the fixed combination are not approved drugs. No licensed pharmacy can legally compound the fixed blend. The premixed vials sold by research vendors and some clinics are gray-market products.

• Raising the body's own growth hormone and IGF-1
• Visceral and abdominal fat outside the approved HIV lipodystrophy setting
• Body composition and lean mass
• Sleep quality and recovery
• Off-label metabolic protocols

Once daily in the evening is the usual pattern. Many run it 5 nights per week. Cycles often run 8 to 12 weeks with a break.

Separate-vial protocols inject tesamorelin 1 to 2 mg under the skin plus ipamorelin 100 to 300 mcg in the same evening fasted session. The pair is also sold as one premixed research vial at a fixed mass ratio. Common ratios are tesamorelin 6 mg with ipamorelin 2 mg (3:1), 10 mg with 5 mg (2:1), and 5 mg with 5 mg (1:1). A locked ratio cannot hit both component targets at once. Dosing a 3:1 vial to a full 1.5 mg tesamorelin dose delivers about 500 mcg ipamorelin. That sits above the usual 200 to 300 mcg ipamorelin range. A 1:1 vial delivers about 1.5 mg ipamorelin at the same tesamorelin dose. That runs five to seven times the usual range. Dosing instead to keep ipamorelin near 200 to 300 mcg holds tesamorelin under about 900 mcg. That falls below its own 1.4 to 2 mg use.

• Separate vials let tesamorelin follow its own label dose while ipamorelin stays in its usual community range
• A premixed vial locks the two doses to one ratio so they can no longer be set independently
• Read the vial label rather than the blend name because the printed ratio sets what each dose delivers
• No compatibility source describes drawing separate tesamorelin and ipamorelin vials into one syringe

No combination pharmacokinetic study exists. The two components clear at different rates. Tesamorelin has a labeled subcutaneous half-life of 8 to 11 minutes. Ipamorelin has a measured human intravenous half-life of about 2 hours. A single blend half-life would be misleading.

Labeled tesamorelin has formulation-specific storage that a research blend does not inherit. Egrifta WR stays at room temperature for 7 days after mixing. Egrifta SV is discarded right after mixing. A premixed research blend or separate research vials carry no approved storage guidance.

• Injection-site redness, itching, pain, swelling, or local lumps
• Joint pain, muscle aches, swelling, tingling hands, or carpal tunnel symptoms
• Higher fasting glucose, reduced insulin sensitivity, or diabetes-range HbA1c
• IGF-1 above the age-adjusted range
• Nausea, vomiting, low potassium, or insomnia reported in intravenous ipamorelin studies
• Rash, hives, swelling, or trouble breathing can signal hypersensitivity

• Tesamorelin

  1 to 2 mg per separate injection or roughly 300 to 900 mcg per premix dose kept in ipamorelin's range

• Ipamorelin

  100 to 300 mcg per separate injection or 500 to 1,500 mcg per premix dose taken to a full tesamorelin amount

Tesamorelin activates the growth hormone releasing hormone receptor on the pituitary. Ipamorelin activates the separate ghrelin receptor on the same gland. Both signals make the pituitary release a pulse of the body's own growth hormone. That growth hormone then raises IGF-1 from the liver. Tesamorelin is the full 44 amino acid releasing hormone with a chemical cap that slows its breakdown. Ipamorelin is a short five amino acid peptide from the growth hormone releasing peptide series. The rationale for combining them is older human work in which a releasing hormone and a ghrelin-type peptide raised the growth hormone pulse more together than either did alone. That work used other releasing peptides rather than ipamorelin. No study shows the pair outperforms either component alone.

Direct evidence for tesamorelin plus ipamorelin is very low. No randomized trial, human pharmacokinetic study, animal study, or case series has tested the exact pair. Tesamorelin alone carries randomized trial evidence for reducing excess abdominal fat in adults with HIV lipodystrophy. That evidence does not transfer to healthy users or to nonprescription blends. Ipamorelin has one human pharmacokinetic study given by vein and one failed postoperative ileus trial. Neither component has a published trial by the subcutaneous route the community uses. Older human work supports the general idea that a releasing hormone and a releasing peptide can amplify each other. That work never used this pair. The pairing rests on community practice rather than any trial of the combination.

• Both components are banned in sport at all times under WADA class S2
• Active or prior cancer is a reason to avoid the pair because tesamorelin is contraindicated in active malignancy and growth hormone signaling can support cell growth
• Pregnancy and breastfeeding should avoid it because tesamorelin caused fluid on the brain in rat offspring and ipamorelin has no reproductive data
• Diabetes, prediabetes, high IGF-1, or untreated sleep apnea needs clinician review because tesamorelin alone more than tripled the odds of crossing into diabetes
• Ipamorelin carries FDA-flagged compounding safety concerns, serious adverse events including death reported with intravenous use, and no subcutaneous human safety study
• A premixed vial dosed to a full tesamorelin amount can deliver 500 to 1,500 mcg ipamorelin and overshoot its usual 200 to 300 mcg range